Literature DB >> 8019618

Pharmacologic erection: time-dependent changes in the corporal environment.

G A Broderick1, R Harkaway.   

Abstract

Priapism is a persistent erection which fails to subside after climax and is accompanied by penile pain and tenderness. The most common form of priapism to confront contemporary urologists is persistence of erection following pharmacologic stimulation. We reviewed our experience over 18 months with initial diagnostic intracavernous challenges of prostaglandin E1. Three-hundred and sixty-six new impotence patients presented to our center and underwent PGE1/color duplex Doppler assessment; 14 patients developed persistent rigidity of two or more hours accompanied by penile discomfort. Each of these patients was successfully managed with penile aspiration and direct corporal instillation of the alpha-adrenergic agonist phenylephrine. The mean PGE1 dosage injected was 6 micrograms and mean duration of erection preceding aspiration 180 minutes. Penile blood gases were obtained from the initial aspirate in all cases. The duration of pharmacologic erections were correlated with the partial pressures of oxygen, carbon dioxide, bicarbonate and the pH using linear regression analysis. There was a clear trend towards deoxygenation, acidosis, and hypercarbia with prolonged erection (105-342 minutes). The relationship between duration of pharmacologic erection and acidosis/hypercarbia was highly significant.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8019618

Source DB:  PubMed          Journal:  Int J Impot Res        ISSN: 0955-9930            Impact factor:   2.896


  12 in total

Review 1.  Evaluation and management of priapism: 2009 update.

Authors:  Yun-Ching Huang; Ahmed M Harraz; Alan W Shindel; Tom F Lue
Journal:  Nat Rev Urol       Date:  2009-05       Impact factor: 14.432

2.  Diagnostic and therapeutic options for the management of ischemic and nonischemic priapism.

Authors:  Jeffrey Bassett; Jacob Rajfer
Journal:  Rev Urol       Date:  2010

3.  An animal model of ischemic priapism and the effects of melatonin on antioxidant enzymes and oxidative injury parameters in rat penis.

Authors:  Nihat Uluocak; Dogan Atılgan; Fikret Erdemir; Bekir S Parlaktas; Adem Yasar; Unal Erkorkmaz; Ali Akbas
Journal:  Int Urol Nephrol       Date:  2010-01-30       Impact factor: 2.370

Review 4.  Management of priapism: an update for clinicians.

Authors:  Helen R Levey; Robert L Segal; Trinity J Bivalacqua
Journal:  Ther Adv Urol       Date:  2014-12

Review 5.  Contemporary best practice in the evaluation and management of stuttering priapism.

Authors:  Georgios Kousournas; Asif Muneer; David Ralph; Evangelos Zacharakis
Journal:  Ther Adv Urol       Date:  2017-07-04

Review 6.  A pathophysiology-based approach to the management of early priapism.

Authors:  Jason R Kovac; Siu K Mak; Maurice M Garcia; Tom F Lue
Journal:  Asian J Androl       Date:  2012-12-03       Impact factor: 3.285

Review 7.  Priapism: new concepts in the pathophysiology and new treatment strategies.

Authors:  Trinity J Bivalacqua; Arthur L Burnett
Journal:  Curr Urol Rep       Date:  2006-11       Impact factor: 2.862

8.  Noninvasive treatments for iatrogenic priapism: Do they really work? A prospective multicenter study.

Authors:  Mohamad Habous; Mohammed Elkhouly; Osama Abdelwahab; Mohammed Farag; Khaled Madbouly; Talal Altuwaijri; Marco Spilotros; Carlo Bettocchi; Saleh Binsaleh
Journal:  Urol Ann       Date:  2016 Apr-Jun

9.  The possible protective effects of dipyridamole on ischemic reperfusion injury of priapism.

Authors:  Ersagun Karaguzel; Cemil Bayraktar; Omer Kutlu; Esin Yulug; Ahmet Mentese; Ali Ertan Okatan; Fatih Colak; Serap Ozer; Ilke O Kazaz
Journal:  Int Braz J Urol       Date:  2016 Jan-Feb       Impact factor: 1.541

Review 10.  Recent advances in the management of priapism.

Authors:  Asif Muneer; Hussain M Alnajjar; David Ralph
Journal:  F1000Res       Date:  2018-01-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.